Impact Factor
4.36
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
6.42
3,631 total citations
h5-index
59
h5 depth signal
Cited share
86.4%
515 of 596
Total citations
3,631
Citation footprint
Metric signal
6.83
External metric anchor
Self-citation
3.6%
131 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
1,115
China
295
Germany
170
Japan
161
United Kingdom
141
Citing Fields of Research
Liver Diseases
1,137
Hepatitis
1,061
Liver & Colon Cancer
224
Immunology
160
Transplantation
120
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
2,110
Articles tracked across the journal lifetime
Indexed publication set
596
515 cited publications
Last 12 months
212
19.3 publications/month
Open access share
96.2%
204 OA publications in the last year
Leading citing country
United States
1,115 citing publications
Leading citing field
Liver Diseases
1,137 citing publications
Latest tracked publication
20 August 2026
10 recent records available
Coverage & Indexing History
v5n1, Jan. 2021-
v1n1, 2017-
Active Coverage
Research Focus & Classification
Indexed Subjects
Liver Diseases
Hepatitis
Immunology
Liver & Colon Cancer
Issuing & Sponsoring Bodies
sponsoring body
American Association for the Study of Liver Diseases
Broad Categories
Gastroenterology
Hepatitis
Liver Diseases
Substance Abuse
Transplantation
Liver & Colon Cancer
MeSH Descriptors
Gastroenterology
Liver Diseases
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1097/hc9.0000000000001029
Open DOI
Effects of diabetes, obesity, and metabolic syndrome on alcohol-associated liver disease: A systematic review
Background: Alcohol-associated liver disease (ALD) is a leading cause of advanced liver disease and liver transplantation worldwide. Cardiometabolic risk factors (CMRFs) may worsen ALD prognosis. While recent nomenclature acknowledges th...
02
DOI 10.1097/hc9.0000000000001009
Open DOI
Symptom burden is associated with health-related quality of life in symptomatic adults with primary sclerosing cholangitis
Background: The Primary Sclerosing Cholangitis Symptom Assessment Project (PSC-SAP) is a research initiative aimed at developing regulatory-grade PSC-specific symptom measures. During the initial screening phase for PSC-SAP, patient-repo...
03
DOI 10.1097/hc9.0000000000001019
Open DOI
The rate of and risk factors for falls among patients with cirrhosis: A multicenter study
Background: Falls are associated with frailty and are a significant cause of morbidity among the elderly. Due to accelerated physiologic aging, frailty is common among patients with cirrhosis. We sought to identify the patients with cirr...
04
DOI 10.1097/hc9.0000000000001031
Open DOI
The INTEGRATE prospective cohort study: Design and methods to evaluate biopsychosocial determinants of outcomes in early liver transplantation for alcohol-associated liver disease
Background and Aims: Early liver transplantation (eLT) for alcohol-associated liver disease (ALD), defined as transplant evaluation with <6 months of alcohol abstinence, is a life-saving therapy for select patients. However, critical gap...
05
DOI 10.1097/hc9.0000000000001025
Open DOI
A randomized trial of viral vector and adjuvanted protein HBV therapeutic vaccine in people with chronic hepatitis B on nucleos(t)ide analogs
Background: This study assessed the safety, efficacy, and immunogenicity of a therapeutic immunization strategy aimed at reaching a functional cure for chronic hepatitis B (CHB), relying on a heterologous prime-boost with viral vectors C...
06
DOI 10.1097/hc9.0000000000001033
Open DOI
Immune mechanisms and pathophysiology of T cell-mediated pediatric acute liver failure (TC-PALF)
Immune dysregulation in pediatric acute liver failure (PALF) is a distinct phenomenon that has garnered interest with respect to disease outcomes and targeted therapies. Some patients with PALF have an “indeterminate” (iPALF) etiology ra...
07
DOI 10.1097/hc9.0000000000000981
Open DOI
Erratum: A PNPLA3–NACC1–RIPK3 pathway mediates macrophage necroptosis and inflammation in MASLD
Was not provided for this article.
08
DOI 10.1097/hc9.0000000000001035
Open DOI
International survey on the management of portal hypertension
Was not provided for this article.
09
DOI 10.1097/hc9.0000000000001001
Open DOI
Erratum: Resolution of hepatic fibrosis after ZFN-mediated gene editing in the PiZ mouse model of human α1-antitrypsin deficiency
Was not provided for this article.
10
DOI 10.1097/hc9.0000000000001015
Open DOI
Hepatic stellate cell subpopulations in human MASLD-related hepatocellular carcinoma upregulate YAP via geranylgeranyl pyrophosphate
Background: Hepatic stellate cells (HSCs) drive cirrhosis and hepatocellular carcinoma (HCC). Statin use decreases cirrhosis and HCC through unclear mechanisms. We aimed to uncover statin-responsive pathways preventing activation of HSC ...
Bibliographical & Catalog Notes
Some articles in Volume 1 published electronically in 2016.